[ad_1]
Allergic to cats? A team of scientists in Switzerland could have a solution for you.
HypoPet AG, a Swiss-based company, has announced that it is working on a vaccine that could target a "major" feline allergen – Fel d 1 – to which nearly 10% of the western population is allergic, according to the results. of a study on the vaccine.
THE DOG IN THE TEXAS DIES FROM A TOXIC ALGAE FOUND IN THE RIVER, THE OWNER RETURNS:
Unlike other immunotherapies, the vaccine, called HypoCat, works by "immunizing cats against their own major allergen, Fel d 1," the researchers said. In other words, the vaccine would be administered to the cat and not to its allergic owner.
The vaccine was "well tolerated with no overt toxicity," according to a press release. The researchers collected data from four separate studies involving a total of 54 cats.
"We are very pleased to release this data which shows that our HypoCat vaccine is capable of producing high levels of antibodies in cats and that these antibodies can bind and neutralize the allergen Fel d 1 produced by animals. "Dr. Gary Jennings, CEO of HypoPet AG, said in a statement. "This work was a key step in the decision-making process [the] development of HypoCat, the main project of our product portfolio ".
"We are pursuing registration studies and discussions with European and US regulators in the hope of bringing this much needed product to market," added Jennings.
ALLERGY IN SESAME AFFECTS MORE AMERICANS WHEN ONCE THOUGHT AND STUDY IS FIND
In the United States, about three out of 10 people are allergic to cats and dogs, and cat allergies are twice as frequent, according to the Asthma and Allergy of America Foundation.
"Humans and animals could benefit from this treatment because owners of allergic cats would reduce their risk of developing chronic diseases, such as asthma, and become more tolerant of their cats, which could therefore remain in households without needing to be abandoned. animal shelters, "said the researchers of the study
